Observational studyBrain, behavior, and immunity2026
Stimulant use disorder indicative of increased serum soluble intercellular adhesion molecule-1 concentrations with altered brain reward and interoceptive processing.
Observational study in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Stimulant use disorders (STIM): (1) elicit compulsive behaviors that can lead to altered brain structure and function; and (2) trigger inflammatory responses by inducing the release of immune molecules, suggesting potential adverse effects. Our previous findings show that amphetamine use disorder is associated with altered neural processing during reward, interoception, and inhibitory control tasks. To extend these findings, we investigated links between neural processing and inflammation that may contribute to STIM. Participants from the first half of the Tulsa-1000 (T1000) study (n = 500) met criteria for either group: (1) stim+ (n = 49) reported methamphetamines/amphetamines as their current drug of choice and met criteria for past-year STIM; or (2) stim- (n = 90) endorsed no past-year diagnosis other than nicotine use disorder. Immunoassays were used to measure six inflammatory analytes. We examined blood oxygen-level-dependent (BOLD) responses to monetary incentive delay (MID), visceral interoceptive awareness (VIA), and inhibitory control with the stop signal task (SST) performed during functional magnetic resonance imaging. The stim+ group exhibited higher serum soluble intercellular adhesion molecule-1 (sICAM-1) concentrations than the stim- group, no significant differences or associations were found with the other inflammatory factors. Within the stim+ group, greater sICAM-1 levels were associated with: (1) lower right nucleus accumbens (NAc) BOLD signal during MID reward anticipation; and (2) higher right amygdala BOLD signal during interoceptive attention. No significant sICAM-1 associations emerged for the SST in stim+ . Inflammation may play a central role in stimulant use as indicated by increased sICAM-1, which may point to central mechanisms. The association between high inflammation and reduced NAc reward activation or higher interoceptive signals in STIM may reflect an STIM-sICAM-1 feedback loop mechanism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.